River Capital recently concluded its association with Alderley Analytical, signifying a notable liquidity event.
This strategic exit aligns with Alderley Analytical’s acquisition by Synexa Life Sciences, marking a milestone in the firm’s growth journey.
River Capital has announced its divestment from Alderley Analytical. This move comes amidst Alderley’s acquisition by Synexa Life Sciences, a company supported by Gilde Healthcare. River Capital’s investment, which commenced with a six-figure sum from the North West Biomedical Fund in 2015, has yielded substantial returns, promising to deliver over four times the initial funding. This exit showcases River Capital’s effective investment strategy in fostering innovative businesses.
Alderley Analytical, founded in 2013, rapidly expanded post-investment. The firm began operations in 2014 and has developed into a crucial player in the bioanalytical services sector. It employs around 60 highly skilled staff members, serves over 200 clients, and recently moved to state-of-the-art laboratories at Tytherington Business Park.
This growth underscores the commitment to supporting pharmaceutical and biotech industries with bespoke bioanalytical services.
The investment by River Capital not only ensured Alderley Analytical’s expansion but also solidified its position in the bioanalytical field.
The strategic support allowed the company to innovate and deliver high-quality services globally.
Alderley Analytical’s founders capitalised on River Capital’s commitment to nurturing North West businesses. This endeavour enabled substantial growth, assisting in drug development research and testing processes.
River Capital’s Portfolio Director, Jerry Mobbs, remarked on the firm’s success, highlighting its alignments with the region’s biomedical industry.
He stated, “Our investment typifies River Capital’s devotion to fostering innovation,” validating their strategy to empower local enterprises.
Paul Holme from Alderley Analytical expressed gratitude towards River Capital, recognising their support as instrumental in their success.
The acquisition by Synexa Life Sciences represents a promising future. Both parties foresee substantial synergies and commercial opportunities.
Paul Holme emphasised Synexa’s role in accelerating Alderley Analytical’s growth, predicting expansive development plans.— Becoming part of the Synexa Group marks a critical step for Alderley Analytical.
The acquisition underscores a substantial strategic alignment between Alderley Analytical and Synexa Life Sciences.
This partnership is expected to leverage commercial potentials, enhancing bioanalytical capabilities worldwide.
The collaboration is set to drive innovative solutions in the life sciences sector, fostering further industry advancements.
River Capital’s successful exit from Alderley Analytical highlights the effectiveness of strategic investment practices.
The acquisition by Synexa Life Sciences promises expanded horizons for Alderley Analytical.
The strategic exit of River Capital from Alderley Analytical demonstrates a successful investment trajectory.
This acquisition paves the way for significant advancements under Synexa Life Sciences’ leadership.
